Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/57171

TitleBSA/ASN/Pol407 nanoparticles for acute lymphoblastic leukemia treatment
Author(s)Tinoco, Ana Catarina Malheiro
Passos, Marisa Sárria Pereira
Loureiro, Ana Isabel Sá
Parpot, Pier
Espiña, Begoña
Gomes, Andreia C
Cavaco-Paulo, Artur
Ribeiro, Artur
KeywordsAsparaginase
Nanoparticle
Acute Lymphoblastic Leukemia
Hyperammonemia
Ammonia Retention
ZET Assay
Issue date2019
PublisherElsevier
JournalBiochemical Engineering Journal
CitationTinoco, Ana Catarina; Sárria, Marisa P.; Loureiro, Ana; Parpot, Pier; Espiña, Begoña; Gomes, Andreia C.; Cavaco-Paulo, Artur; Ribeiro, Artur, BSA/ASN/Pol407 nanoparticles for Acute Lymphoblastic Leukemia treatment. Biochemical Engineering Journal, 141, 80-88, 2019
Abstract(s)During the treatment of acute lymphoblastic leukemia (ALL) with asparaginase (ASN) there is an accumulation of ammonia in the body as result of asparagine hydrolysis. This accumulation known as hyperammonemia is one of the main side-effects of this therapy. To avoid hyperammonemia is urgent to develop new strategies for ammonia retention. Herein is presented the immobilization of ASN into bovine serum albumin/poloxamer 407 (BSA/Pol407) nanoparticles. The ability of the developed nanoparticles to hydrolyze asparagine while retaining the forming ammonia is also explored. Different percentages of ASN were entrapped into BSA nanoparticles coated with Poloxamer 407 and were prepared by high-pressure homogenization. The nanoparticles were characterized regarding their physico-chemical properties, stability, capacity to retain ammonia and safety using zebrafish embryos as an in vivo model of toxicity. The BSA/ASN25%/Pol407 nanoparticles were selected as the best formulation to hydrolyze asparagine using the lowest nanoparticle concentration. These nanoparticles presented physical characteristics suitable for an intravenous application and were capable to retain the forming ammonia decreasing the negative effect of free ASN on zebrafish survival. These nanoparticles could potentially be used to prevent hyperammonemia during ALL treatment with ASN.
TypeArticle
URIhttp://hdl.handle.net/1822/57171
DOI10.1016/j.bej.2018.10.006
ISSN1369-703X
e-ISSN1369-703X
Publisher versionhttp://www.elsevier.com/locate/issn/1369703X
Peer-Reviewedyes
AccessOpen access
Appears in Collections:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Files in This Item:
File Description SizeFormat 
document_48989_1.pdf1,46 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID